A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

20032,633 citationsJournal Articlebronze Open Access

Authors

Paul G. Richardson · Dana-Farber Cancer Institute

Bart Barlogie · University of Arkansas at Little Rock

James R. Berenson · Cedars-Sinai Medical Center

Seema Singhal · University Medical Center

Sundar Jagannath · Catholic Medical Center

David Irwin

S. Vincent Rajkumar · Mayo Clinic in Arizona

Abstract

Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.

Topics & Keywords

Multiple Myeloma Research and Treatments Ubiquitin and proteasome pathways Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 348, Issue 26, pp. 2609-2617

DOI: 10.1056/nejmoa030288

Field-Weighted Citation Impact: 76.96